Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 75

1.

Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.

Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Kazarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Shire N, Jiang H, Goldman JW; CASPIAN investigators.

Lancet. 2019 Oct 4. pii: S0140-6736(19)32222-6. doi: 10.1016/S0140-6736(19)32222-6. [Epub ahead of print]

PMID:
31590988
2.

May Dyspnea Sensation Influence the Sexual Function in Men With Obstructive Sleep Apnea Syndrome? A Prospective Control Study.

Skoczyński S, Nowosielski K, Minarowski Ł, Brożek G, Oraczewska A, Glinka K, Ficek K, Kotulska B, Tobiczyk E, Skomro R, Mróz R, Barczyk A.

Sex Med. 2019 Sep;7(3):303-310. doi: 10.1016/j.esxm.2019.06.005. Epub 2019 Jul 18.

3.

The Prevalence of Cigarette and E-cigarette Smoking Among Students in Central and Eastern Europe-Results of the YUPESS Study.

Brożek GM, Jankowski M, Lawson JA, Shpakou A, Poznański M, Zielonka TM, Klimatckaia L, Loginovich Y, Rachel M, Gereová J, Golonko J, Naumau I, Kornicki K, Pepłowska P, Kovalevskiy V, Raskiliene A, Bielewicz K, Krištúfková Z, Mróz R, Majek P, Lubanski J, Kaleta D, Pinkas J, Zejda JE.

Int J Environ Res Public Health. 2019 Jun 28;16(13). pii: E2297. doi: 10.3390/ijerph16132297.

4.

Benralizumab for the Prevention of COPD Exacerbations.

Criner GJ, Celli BR, Brightling CE, Agusti A, Papi A, Singh D, Sin DD, Vogelmeier CF, Sciurba FC, Bafadhel M, Backer V, Kato M, Ramírez-Venegas A, Wei YF, Bjermer L, Shih VH, Jison M, O'Quinn S, Makulova N, Newbold P, Goldman M, Martin UJ; GALATHEA Study Investigators; TERRANOVA Study Investigators.

N Engl J Med. 2019 Sep 12;381(11):1023-1034. doi: 10.1056/NEJMoa1905248. Epub 2019 May 20.

PMID:
31112385
5.

Asthma-COPD Overlap-A Discordance Between Patient Populations Defined by Different Diagnostic Criteria.

Barczyk A, Maskey-Warzęchowska M, Górska K, Barczyk M, Kuziemski K, Śliwiński P, Batura-Gabryel H, Mróz R, Kania A, Obojski A, Tażbirek M, Celejewska-Wójcik N, Guziejko K, Brajer-Luftmann B, Korzybski D, Damps-Kostańska I, Krenke R.

J Allergy Clin Immunol Pract. 2019 Sep - Oct;7(7):2326-2336.e5. doi: 10.1016/j.jaip.2019.04.022. Epub 2019 Apr 26.

PMID:
31034998
6.

Noninvasive Ventilation-Facilitated Bronchofiberoscopy in Patients with Respiratory Failure.

Skoczyński S, Minarowski Ł, Tobiczyk E, Oraczewska A, Glinka K, Ficek K, Mróz R, Barczyk A.

Adv Exp Med Biol. 2019;1160:53-64. doi: 10.1007/5584_2019_375.

PMID:
30989590
7.

AMPLIFY: a randomized, Phase III study evaluating the efficacy and safety of aclidinium/formoterol vs monocomponents and tiotropium in patients with moderate-to-very severe symptomatic COPD.

Sethi S, Kerwin E, Watz H, Ferguson GT, Mroz RM, Segarra R, Molins E, Jarreta D, Garcia Gil E.

Int J Chron Obstruct Pulmon Dis. 2019 Mar 22;14:667-682. doi: 10.2147/COPD.S189138. eCollection 2019.

8.

Is it possible to predict, whether BAL salvage is going to be diagnostic?

Skoczyński S, Tobiczyk E, Minarowski Ł, Świerczyńska M, Mróz R, Barczyk A.

Adv Respir Med. 2019;87(1):20-25. doi: 10.5603/ARM.a2019.0004. Epub 2019 Mar 4.

9.

Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial.

Busse WW, Bleecker ER, FitzGerald JM, Ferguson GT, Barker P, Sproule S, Olsson RF, Martin UJ, Goldman M; BORA study investigators.

Lancet Respir Med. 2019 Jan;7(1):46-59. doi: 10.1016/S2213-2600(18)30406-5. Epub 2018 Nov 8. Erratum in: Lancet Respir Med. 2019 Jan;7(1):e1.

PMID:
30416083
10.

Estimates of Medication Expenditure for Ischemic Heart Disease Accompanying Chronic Obstructive Pulmonary Disease.

Rysiak E, Prokop I, Zaręba I, Mróz RM.

Adv Exp Med Biol. 2018;1114:49-55. doi: 10.1007/5584_2018_201.

PMID:
29679364
11.

Improvement in 24-hour bronchodilation and symptom control with aclidinium bromide versus tiotropium and placebo in symptomatic patients with COPD: post hoc analysis of a Phase IIIb study.

Beier J, Mroz R, Kirsten AM, Chuecos F, Gil EG.

Int J Chron Obstruct Pulmon Dis. 2017 Jun 14;12:1731-1740. doi: 10.2147/COPD.S121723. eCollection 2017.

12.

Systematic biobanking, novel imaging techniques, and advanced molecular analysis for precise tumor diagnosis and therapy: The Polish MOBIT project.

Niklinski J, Kretowski A, Moniuszko M, Reszec J, Michalska-Falkowska A, Niemira M, Ciborowski M, Charkiewicz R, Jurgilewicz D, Kozlowski M, Ramlau R, Piwkowski C, Kwasniewski M, Kaczmarek M, Ciereszko A, Wasniewski T, Mroz R, Naumnik W, Sierko E, Paczkowska M, Kisluk J, Sulewska A, Cybulski A, Mariak Z, Kedra B, Szamatowicz J, Kurzawa P, Minarowski L, Charkiewicz AE, Mroczko B, Malyszko J, Manegold C, Pilz L, Allgayer H, Abba ML, Juhl H, Koch F; MOBIT Study Group.

Adv Med Sci. 2017 Sep;62(2):405-413. doi: 10.1016/j.advms.2017.05.002. Epub 2017 Jun 21.

PMID:
28646744
13.

Biological effects of gold mine tailings on the intertidal marine environment in Nova Scotia, Canada.

Doe K, Mroz R, Tay KL, Burley J, Teh S, Chen S.

Mar Pollut Bull. 2017 Jan 15;114(1):64-76. doi: 10.1016/j.marpolbul.2016.08.056. Epub 2016 Oct 3.

PMID:
27697321
14.

Safety of Adding Salmeterol to Fluticasone Propionate in Children with Asthma.

Stempel DA, Szefler SJ, Pedersen S, Zeiger RS, Yeakey AM, Lee LA, Liu AH, Mitchell H, Kral KM, Raphiou IH, Prillaman BA, Buaron KS, Yun Kirby S, Pascoe SJ; VESTRI Investigators.

N Engl J Med. 2016 Sep 1;375(9):840-9. doi: 10.1056/NEJMoa1606356.

15.

Neuroinfection as a Mask of Lung Cancer: A Case Series.

Kuklińska B, Moniuszko-Malinowska A, Mróz R, Pancewicz S, Zajkowska J.

Case Rep Infect Dis. 2016;2016:6061350. doi: 10.1155/2016/6061350. Epub 2016 Apr 30.

16.

Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD.

Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, Thach C, Fogel R, Patalano F, Vogelmeier CF; FLAME Investigators.

N Engl J Med. 2016 Jun 9;374(23):2222-34. doi: 10.1056/NEJMoa1516385. Epub 2016 May 15.

17.

EVALUATION OF THE TREATMENT COSTS OF ASTHMA EXACERBATIONS IN OUTPATIENTS.

Rysiak E, Kuczyńska A, Zareba I, Mróz R, Pałka J.

Acta Pol Pharm. 2016 Jan-Feb;73(1):239-45.

PMID:
27008818
18.

Costs of Treatment of Chronic Obstructive Pulmonary Disease.

Milewska A, Rysiak E, Zareba I, Holownia A, Mroz RM.

Adv Exp Med Biol. 2016;885:67-75. doi: 10.1007/5584_2015_199.

PMID:
26801145
19.

Anti-inflammatory effects of atorvastatin treatment in chronic obstructive pulmonary disease. A controlled pilot study.

Mroz RM, Lisowski P, Tycinska A, Bierla J, Trzeciak PZ, Minarowski L, Milewski R, Lisowska A, Boros P, Sobkowicz B, Duszewska AM, Chyczewska E, Musial WJ, MacNee W.

J Physiol Pharmacol. 2015 Feb;66(1):111-28.

20.

Tregs and HLA-DR expression in sputum cells of COPD patients treated with tiotropium and formoterol.

Holownia A, Wielgat P, Stasiak-Barmuta A, Kwolek A, Jakubow P, Szepiel P, Chyczewska E, Braszko JJ, Mroz RM.

Adv Exp Med Biol. 2015;839:7-12. doi: 10.1007/5584_2014_43.

PMID:
25315616

Supplemental Content

Loading ...
Support Center